Clinical trials: Livedo Vasculitis
Raynaud's Disease
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon.
- Trial name
- NCT00480753
- Testing
- Nitroglycerin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Raynaud Disease
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
In this double-blinded, placebo-controlled, fixed-dose, study patients will be randomly assigned to take placebo or 20 mg tadalafil thrice weekly for 6 weeks.
- Trial name
- NCT00626665
- Testing
- Tadalafil
- Volunteers
- 25 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Systemic Sclerosis
CSL Behring Sclero XIII
Many patients with Scleroderma (Systemic sclerosis) experience damage to blood vessels, mainly to the small arteries. A common manifestation of this is Raynaud's phenomenon (fingers or toes turning white then blue in the cold)…
- Trial name
- NCT02551042
- Testing
- Fibrogammin®P, coagulation factor XIII concentrate (Human), 0.9% sodium chloride
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University College, London
Raynaud's Phenomenon
"As Required" Oral Sildenafil in Raynaud's Phenomenon
The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.
- Trial name
- PROFIL (NCT02050360)
- Testing
- Sildenafil 40 mg, Sildenafil 80 mg
- Where
- France
- Volunteers
- 41 people
- Sponsor
- University Hospital, Grenoble
Systemic Sclerosis, Raynaud Phenomenon
Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot
The goal of this observational pilot data acquisition study is to establish if target users can obtain diagnostic quality images in the clinic, from participants with Systemic Sclerosis (SSc), and SSc spectrum conditions.
- Trial name
- NCT06291142
- Testing
- Observation - Nailfold capillaroscopy
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Raynaud's Phenomenon
Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon
This study represents the first trial to assess the efficacy of oral treprostinil therapy in patients with symptomatic primary or secondary Raynaud's Phenomenon (RP) resistant to vasodilatory therapy.
- Trial name
- NCT02583789
- Testing
- oral treprostinil
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brigham and Women's Hospital
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Raynaud's Disease
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048763
- Testing
- Pletal
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Cardiovascular Diseases, Heart Diseases
Raynaud's Treatment Study (RTS)
To determine the relative efficacy of usual medical care and a course of treatment by thermal biofeedback in reducing vasospastic attacks characteristic of Raynaud's syndrome.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Raynaud's Disease, Vascular Diseases
- Trial name
- NCT00000530
- Testing
- nifedipine, biofeedback (psychology), electromyography
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Raynaud's Disease
Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.
Patients presenting to UIC rheumatology clinic with Raynaud's disorder and scleroderma will be asked to participate. 10 hands of patients with both Raynaud's disorder and scleroderma will be studied.
- Trial name
- NCT02615964
- Testing
- Nova Flow Procedure
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Raynaud's Phenomenon
Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.
- Trial name
- NCT00700518
- Testing
- Glyceryl Trinitrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Procris Pharmaceuticals
Raynaud Disease, Hyperemia
PORH and Response to Cold in Raynaud's Phenomenon.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by…
- Conditions
- Raynaud Disease, Hyperemia, Cold
- Trial name
- REFRAIN (NCT02183779)
- Testing
- post-occlusive hyperemia, cooling box, L-NMMA and Fluconazole dermic injection
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Raynaud Disease
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
The purpose of this study is to determine if Vascana, a novel topical formulation of nitroglycerin, is effective in the treatment and prevention of the symptoms associated with Raynaud's Phenomenon.
- Trial name
- NCT00934427
- Testing
- 0.9% nitroglycerin in TAM cream, vehicle cream
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- MediQuest Therapeutics
Raynaud Phenomenon Due to Trauma, Raynaud Disease
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Objective: To compare the efficacy of topical 10% nifedipine versus 5% sildenafil in patients with secondary Raynaud's phenomenon (RP).
- Conditions
- Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic
- Trial name
- NCT03027674
- Testing
- 10% nifedipine cream, 5% sildenafil cream
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Livedoid Vasculitis
Livedoid Vasculopathy: Strong Association With Smoking, Weak Association With Thrombophilia
A screening of patient histories at the clinics of Dermatology of the universities of Zurich, Basel and Bern is performed in order to identify patients with a history of Livedoid vasculopathy.
- Trial name
- NCT05878327
- Testing
- Thrombophilia screening
- Where
- 3 sites in Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Zurich
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Raynaud, Scleroderma
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud's phenomenon is thought to occur when, in response to cold or emotional stress, there is closure of the digital arteries and cutaneous arterioles leading to the clinical finding of sharp demarcated digital pallor and…
- Trial name
- NCT00498615
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Johns Hopkins University
Raynaud Phenomenon
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Individuals with Raynaud's phenomenon often experience episodes of reduced blood flow to their fingers and toes during times of stress or cold exposure, causing significant discomfort and pain.
- Trial name
- NCT03129178
- Testing
- Concentrated beetroot juice
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Portsmouth
Raynaud Phenomenon, Systemic Sclerosis
Cold Challenge With C21 in RP
This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis.
- Trial name
- NCT04388176
- Testing
- C21
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Vicore Pharma AB
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.
- Conditions
- Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
- Trial name
- NCT00378521
- Testing
- MQX-503
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics